PetVivo Holdings, Inc.: directors' dealings · United States · SEC (Form 4)

About PetVivo Holdings, Inc.

PetVivo Holdings, Inc. is a U.S.-based veterinary biomedical device and animal-health company listed on the NASDAQ in the United States. For French-, Belgian-, and Swiss-based investors, it sits in a niche segment of healthcare with a strong emphasis on intellectual property, product commercialization, and veterinary adoption rather than late-stage pharmaceutical development. The company’s core mission is to manufacture, commercialize, and license innovative medical devices and therapeutics for companion animals, particularly dogs, cats, and horses. Its business model is built around adapting biomaterial and biomedical concepts into practical veterinary products, giving it a differentiated positioning in the animal orthopedics and joint-care market. ([petvivo.com](https://www.petvivo.com/?utm_source=openai)) From a corporate history perspective, PetVivo was incorporated in Nevada in 2009 under a former name and entered its current operating business in 2014 through a reverse merger with PetVivo, Inc., a Minnesota corporation. That history is typical of many micro-cap U.S. listed companies that combine a public listing structure with a proprietary technology platform and a gradual commercialization strategy. The company’s operating footprint is centered in Minneapolis, Minnesota, with SEC filings also referencing Edina, Minnesota, as a principal business location. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1512922/000164117225018617/form10-k.htm?utm_source=openai)) PetVivo’s lead commercial product is Spryng® with OsteoCushion® Technology, a veterinarian-administered intra-articular injectable designed to help manage lameness, joint pain, and osteoarthritis. The company also highlights a broader pipeline of products based on its proprietary biomatrix technology, as well as PrecisePRP®, which it describes as an off-the-shelf PRP product intended for veterinary use. In competitive terms, PetVivo is trying to stand out through patent protection, ease of use in clinical practice, and a focus on conditions where veterinarians need alternatives to conventional symptom-management approaches. ([petvivo.com](https://www.petvivo.com/?utm_source=openai)) Geographically, the business remains primarily U.S.-focused, with commercialization efforts supported by a national distributor network and veterinary-industry partnerships. The company has also used trade shows and veterinary conferences to expand awareness and drive adoption. In its public communications, PetVivo has pointed to distribution milestones, including a 2023 announcement that more than 4,500 Spryng syringes had been distributed during the year, which suggests early commercial traction, though investors should treat such figures as an operating milestone rather than a full measure of sustained market penetration. ([petvivo.com](https://www.petvivo.com/news-1/petvivo-holdings-inc-achieves-distribution-milestone-surpassing-4500-syringes-of-spryng-in-2023?utm_source=openai)) Recent developments indicate that management is broadening the product mix and pushing harder on commercialization. In 2025, PetVivo highlighted revenue growth, cost discipline, expansion of its sales force, and a strategic shift toward the companion-animal market, which is larger and faster-growing than the equine-only opportunity. The company also referenced an AI platform intended to reduce veterinary customer acquisition costs, reinforcing the view that management is seeking operating leverage as it scales. Overall, PetVivo remains a high-risk, high-optionality small-cap healthcare name whose equity story depends on clinical adoption, distribution execution, and the ability to convert its patent portfolio into durable commercial value. ([marketscreener.com](https://www.marketscreener.com/news/petvivo-reports-fiscal-q1-2026-results-ce7c51d9df8df226?utm_source=openai))